Abstract：Objective To investigate the diagnostic value of combined detection of urinary creatinine, prostate-specific antigen (PSA), prostate-specific acid phosphatase (PAP) in patients with prostate cancer (PCa).Methods Sixty patients diagnosed with PCa and admitted to the Department of Urology in our hospital between January 2016 and January 2018 were selected as the PCa group, while sixty hospitalized patients with prostate hyperplasia were chosen as the prostatic hyperplasia group, and another sixty healthy individuals were included as the normal control group. Sarcosine oxidase method was used to detect the content of sarcosine in the samples of the three groups of subjects, and radioimmunoassay was used to determine the levels of PSA and PAP in the three groups of subjects, and the relationship between sarcosine content and serum PSA and pathological grade was compared. Receiver operating characteristic (ROC) curve was used to analyze the diagnostic efficacy of PSA, PAP and urine sarcosine in PCa.Results Serum PSA, PAP and urine sarcosine levels in prostate cancer group were significantly higher than those in prostate hyperplasia group and normal control group, with statistical significance (all P<0.05), while there was no significant difference between prostate hyperplasia group and normal control group (all P>0.05). The results of the Gleason score demonstrated the following:the higher the Gleason score (the lower the differentiation degree and the higher the malignancy degree), the higher the serum PSA, urine sarcosine and PAP levels (all P<0.05). ROC curve analysis revealed that the combined detection of serum PSA, PAP, and urine sarcosine levels exhibited excellent diagnostic efficacy for PCa.Conclusions The combined detection of serum PSA, PAP, and urine sarcosine can enhance the sensitivity and specificity in detecting PCa, thereby facilitating its early diagnosis.
